冰岛免疫球蛋白治疗持续增加

Valgeir Steinn Runólfsson , Björn Rúnar Lúdvíksson , Rannveig Einarsdóttir , Þórunn Óskarsdóttir , Valtýr Thors , Ásgeir Haraldsson
{"title":"冰岛免疫球蛋白治疗持续增加","authors":"Valgeir Steinn Runólfsson ,&nbsp;Björn Rúnar Lúdvíksson ,&nbsp;Rannveig Einarsdóttir ,&nbsp;Þórunn Óskarsdóttir ,&nbsp;Valtýr Thors ,&nbsp;Ásgeir Haraldsson","doi":"10.1016/j.clicom.2022.06.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The use of immunoglobulin treatment has been increasing for various indications. The objective of this study was to evaluate clinical use of immunoglobulin therapy in Iceland, estimate off-label usage and describe possible changes in this treatment option.</p></div><div><h3>Methods</h3><p>All prescriptions for intravenous or subcutaneous immunoglobulin treatment require authorisation from Landspitali University Hospital. Patient information is registered and was retrieved for the period 2010 to 2019.</p></div><div><h3>Results</h3><p>A total of 921 patients received immunoglobulin treatment in the study period, intravenous therapy was given in 895 (97.2%) of the cases. Registered indications were 667, off-label indications were 245 and uncertain were nine. The total annual number of patients receiving immunoglobulin treatment increased from 87 in 2010 to 392 in 2019. The increase in immunoglobulin usage was both for registered and off-label indications, 61 to 309 and 26 to 83, respectively.</p></div><div><h3>Conclusion</h3><p>Continually increasing demand and global shortage dictates careful consideration of indications before initiating or continuing treatment with immunoglobulins.</p></div><div><h3>Key Message</h3><p>With global shortage of immunoglobulins, careful consideration and patient selection is important.</p></div><div><h3>Capsule Summary</h3><p>Increasing immunoglobulin usage improves treatment for many patients. However, immunoglobulins are a limited resource and prudent use is imperative.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000166/pdfft?md5=d2e9a1c98031d58c62b43968b92b97b0&pid=1-s2.0-S2772613422000166-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Continuous increase of immunoglobulin therapy in Iceland\",\"authors\":\"Valgeir Steinn Runólfsson ,&nbsp;Björn Rúnar Lúdvíksson ,&nbsp;Rannveig Einarsdóttir ,&nbsp;Þórunn Óskarsdóttir ,&nbsp;Valtýr Thors ,&nbsp;Ásgeir Haraldsson\",\"doi\":\"10.1016/j.clicom.2022.06.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>The use of immunoglobulin treatment has been increasing for various indications. The objective of this study was to evaluate clinical use of immunoglobulin therapy in Iceland, estimate off-label usage and describe possible changes in this treatment option.</p></div><div><h3>Methods</h3><p>All prescriptions for intravenous or subcutaneous immunoglobulin treatment require authorisation from Landspitali University Hospital. Patient information is registered and was retrieved for the period 2010 to 2019.</p></div><div><h3>Results</h3><p>A total of 921 patients received immunoglobulin treatment in the study period, intravenous therapy was given in 895 (97.2%) of the cases. Registered indications were 667, off-label indications were 245 and uncertain were nine. The total annual number of patients receiving immunoglobulin treatment increased from 87 in 2010 to 392 in 2019. The increase in immunoglobulin usage was both for registered and off-label indications, 61 to 309 and 26 to 83, respectively.</p></div><div><h3>Conclusion</h3><p>Continually increasing demand and global shortage dictates careful consideration of indications before initiating or continuing treatment with immunoglobulins.</p></div><div><h3>Key Message</h3><p>With global shortage of immunoglobulins, careful consideration and patient selection is important.</p></div><div><h3>Capsule Summary</h3><p>Increasing immunoglobulin usage improves treatment for many patients. However, immunoglobulins are a limited resource and prudent use is imperative.</p></div>\",\"PeriodicalId\":100269,\"journal\":{\"name\":\"Clinical Immunology Communications\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2772613422000166/pdfft?md5=d2e9a1c98031d58c62b43968b92b97b0&pid=1-s2.0-S2772613422000166-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Immunology Communications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2772613422000166\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Immunology Communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772613422000166","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景免疫球蛋白治疗在各种适应症中的应用越来越多。本研究的目的是评估冰岛免疫球蛋白治疗的临床使用,估计标签外使用情况,并描述这种治疗方案可能发生的变化。方法所有静脉注射或皮下注射免疫球蛋白的处方均需获得兰德斯皮塔利大学医院的批准。注册并检索了2010年至2019年期间的患者信息。结果研究期间共921例患者接受免疫球蛋白治疗,其中895例(97.2%)患者接受静脉注射治疗。注册适应症667例,说明书外适应症245例,不确定适应症9例。每年接受免疫球蛋白治疗的患者总数从2010年的87人增加到2019年的392人。免疫球蛋白的使用在注册适应症和说明书外适应症中均有所增加,分别为61至309例和26至83例。结论持续增长的需求和全球短缺要求在开始或继续使用免疫球蛋白治疗前仔细考虑适应症。随着全球免疫球蛋白的短缺,仔细考虑和患者选择是重要的。增加免疫球蛋白的使用改善了许多患者的治疗。然而,免疫球蛋白是一种有限的资源,必须谨慎使用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Continuous increase of immunoglobulin therapy in Iceland

Background

The use of immunoglobulin treatment has been increasing for various indications. The objective of this study was to evaluate clinical use of immunoglobulin therapy in Iceland, estimate off-label usage and describe possible changes in this treatment option.

Methods

All prescriptions for intravenous or subcutaneous immunoglobulin treatment require authorisation from Landspitali University Hospital. Patient information is registered and was retrieved for the period 2010 to 2019.

Results

A total of 921 patients received immunoglobulin treatment in the study period, intravenous therapy was given in 895 (97.2%) of the cases. Registered indications were 667, off-label indications were 245 and uncertain were nine. The total annual number of patients receiving immunoglobulin treatment increased from 87 in 2010 to 392 in 2019. The increase in immunoglobulin usage was both for registered and off-label indications, 61 to 309 and 26 to 83, respectively.

Conclusion

Continually increasing demand and global shortage dictates careful consideration of indications before initiating or continuing treatment with immunoglobulins.

Key Message

With global shortage of immunoglobulins, careful consideration and patient selection is important.

Capsule Summary

Increasing immunoglobulin usage improves treatment for many patients. However, immunoglobulins are a limited resource and prudent use is imperative.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
CRISPR/Cas9-mediated RELA and RELC knockout in human regulatory T cells abrogates FOXP3 expression and suppressive function Deficiency of interleukin-1 receptor antagonist: An updated review of the pathogenesis, clinical characteristics, and treatments First report of Mycobacterium chimaera infection in a patient with chronic granulomatous disease Chronic disseminated histoplasmosis in a patient on fingolimod therapy: A case report and review of literature Editorial Board
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1